Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Immatics N.V. announces a $150 million underwritten offering, selling 12,945,916 shares at $8.69 each. Jefferies, Leerink Partners, and Cantor are leading the offering.
PRIVATEAug 25, 2026•about 4 hours ago
Amount Raised
$150 Million
Round Type
Post-IPO Equity
Houston
Investors
CantorLeerink PartnersJefferies
Description
Immatics N.V. has agreed to sell 12,945,916 ordinary shares at $8.69 per share in an underwritten offering. The gross proceeds are expected to be $150 million before deductions. The offering is set to close on August 26, 2026, subject to customary closing conditions
Company Information
Company
Immatics
Location
Houston, Texas, United States
About
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
Read more about Immatics on our homepage: https://immatics.com/
Find us also on:
Twitter: https://twitter.com/immatics
Instagram: https://www.instagram.com/immatics/
YouTube: https://www.youtube.com/channel/UCv7uTpsGXvSNzwSX_xOtYSA
Legal notice: https://immatics.com/imprint/
Don't miss Immatics's next move
Get an email the moment Immatics raises, hires an exec, or expands, usually minutes after it happens.
Houston